Original Research
Accepted on 12 May 2026
Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events
in Pharmacoepidemiology